Deep Brain Stimulation for Alzheimer's Disease
(DBS-PPN-AD Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial explores whether deep brain stimulation (DBS), which uses mild electrical impulses, can improve memory and thinking abilities in individuals with mild Alzheimer's disease. Researchers focus on the pedunculopontine nucleus (PPN) to determine if boosting certain brain waves can slow the disease's progression. The primary goal is to assess the safety and practicality of this approach. Individuals with mild Alzheimer's, who do not have other brain issues and have a caregiver for support, may be suitable candidates for this study. As an unphased trial, it offers participants the chance to contribute to groundbreaking research that could lead to new treatments for Alzheimer's disease.
Will I have to stop taking my current medications?
The trial does not specify if you need to stop taking your current medications, but you must not be taking an acetylcholinesterase inhibitor or memantine unless you have been on a stable dose for at least six months.
What prior data suggests that this technique is safe for Alzheimer's patients?
Research has shown that deep brain stimulation (DBS) is generally well-tolerated and has been used for other brain disorders. In previous studies, patients reported mild side effects like temporary headaches or dizziness, which usually do not last long. DBS involves placing a small device in the brain to send electrical signals to specific areas, such as the pedunculopontine nucleus (PPN) in this study. As this method is still being tested for Alzheimer's, researchers are carefully monitoring for any possible side effects. Since this is an early study, the main focus is on safety and the feasibility of the treatment.12345
Why are researchers excited about this trial?
Most treatments for Alzheimer's disease focus on medications that aim to manage symptoms or slow disease progression, like cholinesterase inhibitors and memantine. But deep brain stimulation (DBS) is different—it targets the brain's electrical activity directly. DBS involves implanting electrodes in the brain, in this case, the Pedunculopontine Nucleus (PPN), to send precise electrical impulses. Researchers are excited because this approach could modulate neural activity in a way that might improve cognitive function, offering a new avenue for treatment beyond traditional drug therapies.
What evidence suggests that deep brain stimulation of the pedunculopontine nucleus is effective for Alzheimer's disease?
Research suggests that deep brain stimulation (DBS) targeting the pedunculopontine nucleus (PPN) might aid in treating Alzheimer's disease. This brain area connects to gamma waves, crucial for memory and thinking. In Alzheimer's patients, these waves are weaker and slower. Stimulating the PPN aims to strengthen these gamma waves, potentially enhancing memory and cognitive skills. Previous studies have shown that DBS can positively affect brain activity, indicating it could be a promising approach for Alzheimer's. However, this treatment is new, and further research is needed to confirm its effectiveness. Participants in this trial will receive the experimental DBS intervention targeting the PPN to evaluate its safety, feasibility, and effects on cognitive outcomes.12467
Who Is on the Research Team?
Taufik A. Valiante, MD PhD FRCS
Principal Investigator
University Health Network, Toronto
Are You a Good Fit for This Trial?
This trial is for individuals with mild Alzheimer's Disease. Participants will have a device implanted in their brain to stimulate the pedunculopontine nucleus and must attend regular follow-up appointments over 12 months. Caregivers are also involved in providing information.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
DBS Implantation
Participants undergo a procedure to implant the DBS device in the PPN, followed by an overnight hospital stay for safety monitoring
Treatment
Participants receive deep brain stimulation of the PPN over a 12-month period, with regular follow-up visits every 3 months
Follow-up
Participants are monitored for safety and effectiveness after treatment, including cognitive assessments and caregiver questionnaires
What Are the Treatments Tested in This Trial?
Interventions
- Deep Brain Stimulation of the Pedunculopontine Nucleus
Find a Clinic Near You
Who Is Running the Clinical Trial?
University Health Network, Toronto
Lead Sponsor
Alzheimer Society of Canada
Collaborator
Brain Canada
Collaborator